Low-Molecular-Weight Heparin (LMWH) for Deep Venous Thrombosis (DVT) Prophylaxis
| Status: | Completed |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - 85 |
| Updated: | 4/2/2016 |
| Start Date: | February 2010 |
| End Date: | December 2013 |
| Contact: | Stan Ragon, M.D. |
| Email: | stanragon@hotmail.com |
| Phone: | 423-778-9202 |
Low-Molecular-Weight Heparin for DVT Prophylaxis After Open Reduction and Internal Fixation of Ankle Fractures: A Randomized, Prospective Trial
1. The use of LMWH following open reduction and internal fixation of ankle fractures will
reduce the number of thrombi formed.
2. The rates of clinically significant DVT will be equivalent between two groups.
reduce the number of thrombi formed.
2. The rates of clinically significant DVT will be equivalent between two groups.
Routine use of thromboprophylaxis may be over treatment and definitely increases healthcare
costs. While prophylaxis may reduce the number of thrombi formed the exact number and
clinical significance of these is unknown. This study seeks to answer the question of
whether or not DVT prophylaxis with low-molecular-weight heparin (LMWH) following ORIF of
ankle fractures is warranted.
costs. While prophylaxis may reduce the number of thrombi formed the exact number and
clinical significance of these is unknown. This study seeks to answer the question of
whether or not DVT prophylaxis with low-molecular-weight heparin (LMWH) following ORIF of
ankle fractures is warranted.
Inclusion Criteria:
- At least 18 years old
- Surgical ankle fracture able to be definitively treated with one operation
Exclusion Criteria:
- Younger than 18 years of age
- Other significant injury
- Known hypercoagulable state
- History of bleeding disorder
- History of DVT
We found this trial at
1
site
Click here to add this to my saved trials
